<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-archivearticle1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">3753249</article-id><article-id pub-id-type="pmid">23991104</article-id><article-id pub-id-type="publisher-id">PONE-D-13-13644</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0072381</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Biology</subject><subj-group><subject>Computational Biology</subject><subj-group><subject>Genomics</subject><subj-group><subject>Genome Analysis Tools</subject><subj-group><subject>Genome-Wide Association Studies</subject></subj-group></subj-group></subj-group><subj-group><subject>Microarrays</subject></subj-group></subj-group><subj-group><subject>Genetics</subject><subj-group><subject>Human Genetics</subject><subj-group><subject>Genetic Association Studies</subject><subject>Genome-Wide Association Studies</subject></subj-group></subj-group><subj-group><subject>Genetics of Disease</subject><subject>Genome-Wide Association Studies</subject></subj-group></subj-group><subj-group><subject>Molecular cell biology</subject><subj-group><subject>Signal transduction</subject><subj-group><subject>Signaling cascades</subject><subj-group><subject>MAPK signaling cascades</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine</subject><subj-group><subject>Neurology</subject><subj-group><subject>Motor Neuron Diseases</subject><subj-group><subject>Amyotrophic Lateral Sclerosis</subject></subj-group></subj-group><subj-group><subject>Neurodegenerative Diseases</subject></subj-group></subj-group></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>Genome-Wide Copy Number Variation in Sporadic Amyotrophic Lateral Sclerosis in the Turkish Population: Deletion of EPHA3 Is a Possible Protective Factor </plain></SENT>
</text></SecTag></article-title><alt-title alt-title-type="running-head">Copy Number Variation in Turkish ALS Patients</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Uyan</surname><given-names>Özgün</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Ömür</surname><given-names>Özgür</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Ağım</surname><given-names>Zeynep Sena</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Özoğuz</surname><given-names>Aslıhan</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Hong</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Parman</surname><given-names>Yeşim</given-names></name><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Deymeer</surname><given-names>Feza</given-names></name><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Oflazer</surname><given-names>Piraye</given-names></name><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Koç</surname><given-names>Filiz</given-names></name><xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Tan</surname><given-names>Ersin</given-names></name><xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Özçelik</surname><given-names>Hilmi</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref><xref ref-type="aff" rid="aff6">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Başak</surname><given-names>A. Nazlı</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="corresp" rid="cor1">
<sup>*</sup>
</xref></contrib></contrib-group><aff id="aff1">
<label>1</label>
<addr-line>Suna and İnan Kıraç Foundation Neurodegeneration Research Laboratory, Molecular Biology and Genetics Department, Bogazici University, Istanbul, Turkey</addr-line>
</aff><aff id="aff2">
<label>2</label>
<addr-line>Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Canada</addr-line>
</aff><aff id="aff3">
<label>3</label>
<addr-line>Neurology Department, Istanbul Medical School, Istanbul University, Istanbul, Turkey</addr-line>
</aff><aff id="aff4">
<label>4</label>
<addr-line>Neurology Department, Medical School, Çukurova University, Adana, Turkey</addr-line>
</aff><aff id="aff5">
<label>5</label>
<addr-line>Neurology Department, Hacettepe University, Ankara, Turkey</addr-line>
</aff><aff id="aff6">
<label>6</label>
<addr-line>Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada</addr-line>
</aff><contrib-group><contrib contrib-type="editor"><name><surname>Cookson</surname><given-names>Mark R.</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">
<addr-line>National Institutes of Health, United States of America</addr-line>
</aff><author-notes><corresp id="cor1">* E-mail: <email>basak@boun.edu.tr</email></corresp><fn fn-type="COI-statement"><p><text><SENT sid="1" pm="."><plain>Competing Interests: The authors have declared that no competing interests exist. </plain></SENT>
</text></p></fn><fn fn-type="con"><p><text><SENT sid="2" pm="."><plain>Conceived and designed the experiments: ÖU ZSA HÖ ANB. </plain></SENT>
<SENT sid="3" pm="."><plain>Performed the experiments: ÖU ZSA ÖÖ. </plain></SENT>
<SENT sid="4" pm="."><plain>Analyzed the data: ÖU ÖÖ ZSA HÖ ANB. </plain></SENT>
<SENT sid="5" pm="."><plain>Contributed reagents/materials/analysis tools: ÖU ZSA ÖÖ AÖ HL YP FD PO FK ET. </plain></SENT>
<SENT sid="6" pm="."><plain>Wrote the paper: ÖU ZSA ÖÖ HÖ ANB. </plain></SENT>
</text></p></fn></author-notes><pub-date pub-type="collection"><year>2013</year></pub-date><pub-date pub-type="epub"><day>26</day><month>8</month><year>2013</year></pub-date><volume>8</volume><issue>8</issue><elocation-id>e72381</elocation-id><history><date date-type="received"><day>29</day><month>3</month><year>2013</year></date><date date-type="accepted"><day>8</day><month>7</month><year>2013</year></date></history><permissions><copyright-statement>© 2013 Uyan et al</copyright-statement><copyright-year>2013</copyright-year><copyright-holder>Uyan et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.</license-p></license></permissions><abstract><p><SecTag type="ABS"><text><SENT sid="7" pm="."><plain>The genome-wide presence of copy number variations (CNVs), which was shown to affect the expression and function of genes, has been recently suggested to confer risk for various human disorders, including Amyotrophic Lateral Sclerosis (ALS). </plain></SENT>
<SENT sid="8" pm="."><plain>We have performed a genome-wide CNV analysis using PennCNV tool and 733K GWAS data of 117 Turkish ALS patients and 109 matched healthy controls. </plain></SENT>
<SENT sid="9" pm="."><plain>Case-control association analyses have implicated the presence of both common (&gt;5%) and rare (&lt;5%) CNVs in the Turkish population. </plain></SENT>
<SENT sid="10" pm="."><plain>In the framework of this study, we identified several common and rare loci that may have an impact on ALS pathogenesis. </plain></SENT>
<SENT sid="11" pm="."><plain>None of the CNVs associated has been implicated in ALS before, but some have been reported in different types of cancers and autism. </plain></SENT>
<SENT sid="12" pm="."><plain>The most significant associations were shown for 41 kb and 15 kb intergenic heterozygous deletions (Chr11: 50,545,009–50,586,426 and Chr19: 20,860,930–20,875,787) both contributing to increased risk for ALS. </plain></SENT>
<SENT sid="13" pm="."><plain>CNVs in coding regions of the MAP4K3, HLA-B, EPHA3 and DPYD genes were detected however, after validation by Log R Ratio (LRR) values and TaqMan CNV genotyping, only EPHA3 deletion remained as a potential protective factor for ALS (p = 0.0065024). </plain></SENT>
<SENT sid="14" pm="."><plain>Based on the knowledge that EPHA4 has been previously shown to rescue SOD1 transgenic mice from ALS phenotype and prolongs survival, EPHA3 may be a promising candidate for therepuetic interventions. </plain></SENT>
</text></SecTag></p></abstract><funding-group><funding-statement>This study was funded by Suna and Inan Kıraç Foundation (<ext-link ext-link-type="uri" xlink:href="http://en.kiraca.com.tr/Corp-Responsibility/detail_kiracfoundation.aspx?SectionID=C2%2bWE3CIWXkxHtpw8lqgFA%3d%3d&amp;ContentId=faQeVeZudHFv1A4ACnP5uA%3d%3d">http://en.kiraca.com.tr/Corp-Responsibility/detail_kiracfoundation.aspx?SectionID=C2%2bWE3CIWXkxHtpw8lqgFA%3d%3d&amp;ContentId=faQeVeZudHFv1A4ACnP5uA%3d%3d</ext-link>), Bogaziçi University Research Funds (<ext-link ext-link-type="uri" xlink:href="http://www.arastirma.boun.edu.tr/arastirma.php?a_l=tr&amp;p=130">http://www.arastirma.boun.edu.tr/arastirma.php?a_l=tr&amp;p=130</ext-link>) and The Scientific and Technological Research Council of Turkey (TUBITAK) (project ID:109S075). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><page-count count="8"/></counts></article-meta></front><body><SecTag type="INTRO"><sec id="s1"><title><text><SENT sid="15" pm="."><plain>Introduction </plain></SENT>
</text></title><p><text><SENT sid="16" pm="."><plain>Amyotrophic lateral sclerosis (ALS) is a complex neurodegenerative disorder impacted by genetic and environmental factors. </plain></SENT>
<SENT sid="17" pm="."><plain>The disease presents as familial ALS (fALS) in 10% of patients, whereas the remaining 90% represents the non-familial form, called sporadic ALS (sALS) [1]. </plain></SENT>
<SENT sid="18" pm="."><plain>The genome-wide presence of copy number variations (CNVs), which was shown to affect the expression and function of genes, has been recently suggested to confer risk for various human disorders, including ALS. </plain></SENT>
<SENT sid="19" pm="."><plain>To date, using high-density genome-wide single nucleotide polymorphism (SNP) data, four studies restricted to European and US-European ALS populations investigated the presence of CNVs. </plain></SENT>
<SENT sid="20" pm="."><plain>Cronin et al. identified several candidates, including the deletion in C14orf177, and deletion and duplication of the GSDMDC1 and STS genes among 408 Irish and 868 Dutch individuals, respectively [2]. </plain></SENT>
<SENT sid="21" pm="."><plain>Blauw et al. investigated 406 patients with sporadic ALS versus 404 controls and identified several candidates, such as deletion of the CLEC3A and WWOX genes [3]. </plain></SENT>
<SENT sid="22" pm="."><plain>Wain et al. analyzed 730 ALS cases and 789 controls to find CNVs associated with ALS. </plain></SENT>
<SENT sid="23" pm="."><plain>They reported several intergenic and gene loci, including two top coding candidates, e.g. duplications of the RDH13 and FBXL2 genes [4]. </plain></SENT>
<SENT sid="24" pm="."><plain>Blauw et al., conducted a genome-wide screen of 1,875 cases and 8,731 controls (including over 8,000 individuals in replication set), this study revealed deletions and duplications of DPP6 and deletions of NIPA1 loci to be candidates for ALS development [5]. </plain></SENT>
</text></p><p><text><SENT sid="25" pm="."><plain>In a recent study, duplication of the SMN1 gene, responsible for spinal muscular atrophy, has been associated with sALS [6]; furthermore, homozygous SMN2 deletions were found to be protective in the Swedish population [7]. </plain></SENT>
<SENT sid="26" pm="."><plain>In this study, we have investigated for the first time the presence of CNVs in a Turkish ALS cohort with matched healthy controls; we were able to identify several candidates that may impact the development of ALS in the Turkish population. </plain></SENT>
</text></p></sec></SecTag><SecTag type="METHODS"><sec sec-type="materials|methods" id="s2"><title><text><SENT sid="27" pm="."><plain>Materials and Methods </plain></SENT>
</text></title><sec id="s2a"><title><text><SENT sid="28" pm="."><plain>Ethics Statement </plain></SENT>
</text></title><p><text><SENT sid="29" pm="."><plain>Written informed consent was taken from all patients involved in this study. </plain></SENT>
<SENT sid="30" pm="."><plain>Written consent for affected children/minors was obtained from their parents. </plain></SENT>
<SENT sid="31" pm="."><plain>The approval of the use of patient samples was obtained from the Ethics Committee of Bogaziçi University, Istanbul. </plain></SENT>
<SENT sid="32" pm="."><plain>Control samples were collected anonymously from the Microbiology Department of Haydarpasa State Hospital, Istanbul. </plain></SENT>
<SENT sid="33" pm="."><plain>The control samples used in this study were described in a previous publication [8]. </plain></SENT>
</text></p></sec><sec id="s2b"><title><text><SENT sid="34" pm="."><plain>Study Population and Pre-CNV Analysis </plain></SENT>
</text></title><p><text><SENT sid="35" pm="."><plain>Sporadic ALS patients were referred to our center from different hospitals and neurology clinics throughout Turkey. </plain></SENT>
<SENT sid="36" pm="."><plain>El Escorial Criteria were applied for clinical diagnosis [9]. </plain></SENT>
<SENT sid="37" pm="."><plain>Genotyping, using the Illumina HumanOmniExpress 733K SNP array chip, was performed for 117 Turkish sALS patients and 109 ethnic, gender- and age-matched healthy controls. </plain></SENT>
<SENT sid="38" pm="."><plain>All samples had a high quality genotyping rate (genotype call &gt;98%, total genotyping rate: 0.994). </plain></SENT>
<SENT sid="39" pm="."><plain>The mean age of onset was 47.8 (age range: 17–79) for cases and the mean age was 53.4 for controls (age range: 23–84). </plain></SENT>
<SENT sid="40" pm="."><plain>The gender proportion of male to female was 1.32 for cases and 1.4 for controls. </plain></SENT>
</text></p></sec><sec id="s2c"><title><text><SENT sid="41" pm="."><plain>CNV Analysis and Post-CNV Calling </plain></SENT>
</text></title><p><text><SENT sid="42" pm="."><plain>PennCNV software was used for quality control and CNV analysis [10]. </plain></SENT>
<SENT sid="43" pm="."><plain>The raw GWAS SNP information, including Log R Ratio (LRR) and B allele frequencies (BAF) values were extracted for each individual. </plain></SENT>
<SENT sid="44" pm="."><plain>First, CNV calls were maintained with confidence scores using default parameters without any criteria yielding a total of 25,000 CNVs. </plain></SENT>
<SENT sid="45" pm="."><plain>We applied a set of filtering criteria (as recommended by the algorithm) to exclude poor quality samples and used the GC model signal adjustment to reduce false positive calls in individuals with high fluctuation of genomic signal waviness. </plain></SENT>
<SENT sid="46" pm="."><plain>After signal adjustment, individuals with &gt;100 CNVs were excluded from analysis. </plain></SENT>
<SENT sid="47" pm="."><plain>To discard false positives, the generated CNV calls were also filtered using confidence value scores provided for each sample by PennCNV output. </plain></SENT>
<SENT sid="48" pm="."><plain>A confidence score of 10 or larger has been suggested as a threshold to classify reliable CNV calls [11]. </plain></SENT>
<SENT sid="49" pm="."><plain>After elimination of individuals and CNV calls with a low confidence value (conf&lt;10), approximately 5,000 CNV calls were obtained and included in the final analysis. </plain></SENT>
</text></p></sec><sec id="s2d"><title><text><SENT sid="50" pm="."><plain>Defining the CNV Loci </plain></SENT>
</text></title><p><text><SENT sid="51" pm="."><plain>CNV calls were grouped into loci having an intersection of at least 1 kb. </plain></SENT>
<SENT sid="52" pm="."><plain>The overlapping parts of CNV calls were defined as CNV loci. </plain></SENT>
<SENT sid="53" pm="."><plain>Each of these CNV loci represents all CNV calls that were present in that particular region. </plain></SENT>
<SENT sid="54" pm="."><plain>To identify CNV loci that are novel, we compared our results with those published in the Database of Genomic Variants (DGV) [12]. </plain></SENT>
<SENT sid="55" pm="."><plain>We used the gene annotation of the University of California Santa Cruz (UCSC) Genome Browser (<ext-link ext-link-type="uri" xlink:href="http://genome.ucsc.edu/">http://genome.ucsc.edu/</ext-link>) [13] to identify genes that were located within or partially overlapped with CNV loci. </plain></SENT>
</text></p></sec><sec id="s2e"><title><text><SENT sid="56" pm="."><plain>Validating CNV Calls by Interpreting Log R Ratios (LRRs) </plain></SENT>
</text></title><p><text><SENT sid="57" pm="."><plain>We additionally analyzed the top candidate regions, identified by the PennCNV tool to see whether PennCNV detected CNV calls properly. </plain></SENT>
<SENT sid="58" pm="."><plain>Individuals were categorized into two groups, controls without CNV versus patients and controls with CNV. </plain></SENT>
<SENT sid="59" pm="."><plain>The LRR values, obtained from SNP genotyping data, were extracted within the candidate CNV regions, as well as regions in the proximity of CNV loci. </plain></SENT>
<SENT sid="60" pm="."><plain>Average LRRs of SNPs in both groups were calculated and plotted for comparison. </plain></SENT>
<SENT sid="61" pm="."><plain>t-test and Mann-Whitney U test were applied to LRR value of each SNP in both groups for statistical significance. </plain></SENT>
<SENT sid="62" pm="."><plain>p-value of threshold is defined as p&lt;0.0005. </plain></SENT>
</text></p></sec><sec id="s2f"><title><text><SENT sid="63" pm="."><plain>Validation of CNV Calls Using Quantitative PCR </plain></SENT>
</text></title><p><text><SENT sid="64" pm="."><plain>To validate the candidate CNVs in the MAP4K3, HLA-B and EPHA3 gene regions, TaqMan assays Hs02852136_cn, Hs03605931_cn and Hs03458738_cn were used for genotyping each locus, respectively. </plain></SENT>
<SENT sid="65" pm="."><plain>TaqMan Copy Number Reference Assay (genotyping human the RNase P gene) was used as reference. </plain></SENT>
<SENT sid="66" pm="."><plain>Experiments were performed according to the manufacturer’s instructions and StepOnePlus instrument (Applied Biosystems Inc., USA) was used for qPCR. </plain></SENT>
<SENT sid="67" pm="."><plain>For the CNV analysis, CT values were obtained from StepOne Software v.2.2.2 (Applied Biosystems Inc., USA) and then imported to Copy Caller Software v.2.0 (Applied Biosystems Inc., USA) to determine copy numbers. </plain></SENT>
</text></p></sec><sec id="s2g"><title><text><SENT sid="68" pm="."><plain>Statistical Analysis </plain></SENT>
</text></title><p><text><SENT sid="69" pm="."><plain>Fisher’s exact test was used to carry out the case-control association analysis of CNVs identified in the Turkish population. </plain></SENT>
<SENT sid="70" pm="."><plain>No multiple testing was applied. </plain></SENT>
<SENT sid="71" pm="."><plain>The significance threshold was chosen as p&lt;0.05. </plain></SENT>
<SENT sid="72" pm="."><plain>For comparison of CNV sizes and mean numbers per individual between cases and controls, two-tailed Mann-Whitney U test was used. </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="RESULTS"><sec id="s3"><title><text><SENT sid="73" pm="."><plain>Results </plain></SENT>
</text></title><sec id="s3a"><title><text><SENT sid="74" pm="."><plain>Genome-wide CNV Analysis </plain></SENT>
</text></title><p><text><SENT sid="75" pm="."><plain>Analysis of the 733K GWAS markers using LRR and BAF values, yielded ∼25,000 CNV calls with default parameters. </plain></SENT>
<SENT sid="76" pm="."><plain>After the GC signal adjustment model, 18,200 CNV calls were generated. </plain></SENT>
<SENT sid="77" pm="."><plain>In addition, individuals with high number of CNV calls, and CNV calls with low confidence values were eliminated. </plain></SENT>
<SENT sid="78" pm="."><plain>As a result, two ALS patients and three healthy controls with more than ∼10,000 CNV calls were discarded. </plain></SENT>
<SENT sid="79" pm="."><plain>In addition, 3,000 calls were excluded from CNV analysis due to low confidence threshold (conf&lt;10.00). </plain></SENT>
<SENT sid="80" pm="."><plain>After exclusion of CNV calls based on the above criteria, 4,935 CNVs in 115 ALS patients and 106 controls were considered for further investigation. </plain></SENT>
</text></p></sec><sec id="s3b"><title><text><SENT sid="81" pm="."><plain>Characteristics of the CNVs in Cases and Controls </plain></SENT>
</text></title><p><text><SENT sid="82" pm="."><plain>Among 4,935 CNV calls detected, 2,736 were found in cases and 2,199 in controls. </plain></SENT>
<SENT sid="83" pm="."><plain>The average number of all types of CNVs per individual were significantly higher in ALS patients (23.8) compared to controls (20.7) (p = 0.002). </plain></SENT>
<SENT sid="84" pm="."><plain>In addition, the range of CNV lengths was also significantly higher in cases (87.1 kb) as compared to controls (85.2 kb) (p = 0.012) (Table 1). </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="pone-0072381-t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0072381.t001</object-id><label>Table 1</label><caption><title><text><SENT sid="85" pm="."><plain>Summary Statistics of CNV screening in 115 ALS patients and 106 controls. </plain></SENT>
</text></title></caption><alternatives><graphic id="pone-0072381-t001-1" xlink:href="pone.0072381.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="86" pm="."><plain>Categories </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="87" pm="."><plain>ALS patients </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="88" pm="."><plain>Control </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="89" pm="."><plain>p-value </plain></SENT>
</text></td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="90" pm="."><plain>Average CNV number per individual (Range) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="91" pm="."><plain>23.8 (9–85) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="92" pm="."><plain>20.7 (7–76) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="93" pm="."><plain>0.002 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="94" pm="."><plain>Average CNV length (kb)/(Range of lengths) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="95" pm="."><plain>87.1/(97 bp–8,438 kb) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="96" pm="."><plain>85.2/(33 bp–3,538 kb) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="97" pm="."><plain>0.012 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="98" pm="."><plain>Average SNP number per CNV (Range) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="99" pm="."><plain>14.21 (3–311) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="100" pm="."><plain>15.45 (3–322) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="101" pm="."><plain>0.209 </plain></SENT>
</text></td></tr></tbody></table></alternatives></table-wrap></SecTag><p><text><SENT sid="102" pm="."><plain>We have also investigated the type of CNVs (duplications, heterozygous and homozygous deletions) in cases and controls. </plain></SENT>
<SENT sid="103" pm="."><plain>Out of 2736 CNV calls in ALS patients, 1115 CNVs were duplications and the rest were deletions. </plain></SENT>
<SENT sid="104" pm="."><plain>In controls, 868 duplications and 1331 deletions were detected. </plain></SENT>
<SENT sid="105" pm="."><plain>Two-tailed Mann-Whitney U test has shown statistically significant association of mean duplication per individual in cases (9.78) compared to controls (8.19) (p = 0.001). </plain></SENT>
<SENT sid="106" pm="."><plain>Median size of heterozygous deletions were also found to be significant in ALS cases (27.39) as compared to controls (22.8) (p = 0.024) (Table 2). </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="pone-0072381-t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0072381.t002</object-id><label>Table 2</label><caption><title><text><SENT sid="107" pm="."><plain>Characteristics of CNV calls. </plain></SENT>
</text></title></caption><alternatives><graphic id="pone-0072381-t002-2" xlink:href="pone.0072381.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="108" pm="."><plain>Type of CNV </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="109" pm="."><plain>Cases </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="110" pm="."><plain>Controls </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="111" pm="."><plain>p value </plain></SENT>
</text></td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="112" pm="."><plain>Duplication </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="113" pm="."><plain>Total </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="114" pm="."><plain>1115 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="115" pm="."><plain>868 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="116" pm="."><plain>Mean per individual (Range) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="117" pm="."><plain>9.78 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="118" pm="."><plain>8.19 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="119" pm="."><plain>0.001 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="120" pm="."><plain>Median Size, kb (Range) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="121" pm="."><plain>53.85 (0–1448) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="122" pm="."><plain>53.52(0–869) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="123" pm="."><plain>0.702 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="124" pm="."><plain>Heterozygous deletion </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="125" pm="."><plain>Total </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="126" pm="."><plain>1404 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="127" pm="."><plain>1099 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="128" pm="."><plain>Mean per individual (Range) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="129" pm="."><plain>12.32 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="130" pm="."><plain>10.37 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="131" pm="."><plain>0.116 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="132" pm="."><plain>Median Size, kb (Range) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="133" pm="."><plain>27.39 (0–8438) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="134" pm="."><plain>22.8 (0–3539) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="135" pm="."><plain>0.024 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="136" pm="."><plain>Homozygous deletion </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="137" pm="."><plain>Total </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="138" pm="."><plain>217 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="139" pm="."><plain>232 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="140" pm="."><plain>Mean per individual (Range) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="141" pm="."><plain>1.90 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="142" pm="."><plain>2.19 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="143" pm="."><plain>0.257 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="144" pm="."><plain>Median Size, kb (Range) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="145" pm="."><plain>4.69 (0–337) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="146" pm="."><plain>3.87 (0–338) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="147" pm="."><plain>0.956 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="148" pm="."><plain>Total number of CNVs </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="149" pm="."><plain>2736 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="150" pm="."><plain>2199 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/></tr></tbody></table></alternatives></table-wrap></SecTag></sec><sec id="s3c"><title><text><SENT sid="151" pm="."><plain>Frequent CNVs </plain></SENT>
</text></title><p><text><SENT sid="152" pm="."><plain>Case-control association analyses have implicated the presence of both common (frequency&gt;5%) and rare (frequency&lt;5%) CNVs in the Turkish population. </plain></SENT>
<SENT sid="153" pm="."><plain>Among the 20 statistically significant (p&lt;0.05) common CNV loci located within intergenic and gene coding regions, two third represented single copy losses (heterozygous deletion) with an exception of a homozygous deletion, and one third copy number gains (Table 3). </plain></SENT>
<SENT sid="154" pm="."><plain>Out of 20 CNVs, six represented gains, whereas 14 were losses, including 13 heterozygous and one homozygous deletion. </plain></SENT>
<SENT sid="155" pm="."><plain>Six out of 20 CNVs had higher frequencies in controls, thus representing changes protective for ALS. </plain></SENT>
<SENT sid="156" pm="."><plain>The remaining 14 CNVs had low frequencies in controls (&lt;2%), accounting for increased ALS risk. </plain></SENT>
<SENT sid="157" pm="."><plain>Among the 20, 18 were previously reported [14], [15], [16], [17] in DGV and two, MAP4K3 (mitogen-activated protein kinase kinase kinase kinase 3) and the intergenic locus (chr3: 84,486,776–84,510,027), were novel. </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="pone-0072381-t003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0072381.t003</object-id><label>Table 3</label><caption><title><text><SENT sid="158" pm="."><plain>Association results of CNVs observed in analysis with p&lt;0.05 (Fisher’s Exact Test). </plain></SENT>
</text></title></caption><alternatives><graphic id="pone-0072381-t003-3" xlink:href="pone.0072381.t003"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="159" pm="."><plain>Chr </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="160" pm="."><plain>Start (bp) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="161" pm="."><plain>End (bp) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="162" pm="."><plain>Change </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="163" pm="."><plain>Novel/reported </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="164" pm="."><plain>ALS </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="165" pm="."><plain>% </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="166" pm="."><plain>Control </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="167" pm="."><plain>% </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="168" pm="."><plain>p value </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="169" pm="."><plain>Intergenic/Gene region </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="170" pm="."><plain>Gene Name </plain></SENT>
</text></td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="171" pm="."><plain>11 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="172" pm="."><plain>50,545,009 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="173" pm="."><plain>50,586,426 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="174" pm="."><plain>loss </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="175" pm="."><plain>r </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="176" pm="."><plain>21 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="177" pm="."><plain>18.42 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="178" pm="."><plain>2 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="179" pm="."><plain>1.89 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="180" pm="."><plain>2.94E-05 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="181" pm="."><plain>intergenic </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="182" pm="."><plain>19 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="183" pm="."><plain>20,860,930 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="184" pm="."><plain>20,875,787 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="185" pm="."><plain>loss </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="186" pm="."><plain>r </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="187" pm="."><plain>15 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="188" pm="."><plain>13.16 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="189" pm="."><plain>2 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="190" pm="."><plain>1.89 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="191" pm="."><plain>0.001320 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="192" pm="."><plain>intergenic </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="193" pm="."><plain>2 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="194" pm="."><plain>39,372,016 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="195" pm="."><plain>39,428,488 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="196" pm="."><plain>gain </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="197" pm="."><plain>n </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="198" pm="."><plain>14 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="199" pm="."><plain>12.28 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="200" pm="."><plain>2 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="201" pm="."><plain>1.89 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="202" pm="."><plain>0.0023976 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="203" pm="."><plain>MAP4K3 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="204" pm="."><plain>mitogen-activated protein kinase kinase kinase kinase 3 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="205" pm="."><plain>3 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="206" pm="."><plain>84,486,776 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="207" pm="."><plain>84,510,027 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="208" pm="."><plain>gain </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="209" pm="."><plain>n </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="210" pm="."><plain>11 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="211" pm="."><plain>9.65 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="212" pm="."><plain>1 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="213" pm="."><plain>0.94 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="214" pm="."><plain>0.0037285 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="215" pm="."><plain>intergenic </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="216" pm="."><plain>6 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="217" pm="."><plain>31,389,749 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="218" pm="."><plain>31,393,270 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="219" pm="."><plain>loss* </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="220" pm="."><plain>r </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="221" pm="."><plain>8 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="222" pm="."><plain>7.02 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="223" pm="."><plain>0 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="224" pm="."><plain>0.00 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="225" pm="."><plain>0.0045992 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="226" pm="."><plain>HLA-B,HLA-B*0707 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="227" pm="."><plain>major histocompatibility complex, class I, B </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="228" pm="."><plain>5 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="229" pm="."><plain>151,496,845 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="230" pm="."><plain>151,499,002 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="231" pm="."><plain>loss </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="232" pm="."><plain>r </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="233" pm="."><plain>5 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="234" pm="."><plain>4.39 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="235" pm="."><plain>16 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="236" pm="."><plain>15.09 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="237" pm="."><plain>0.0061567 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="238" pm="."><plain>AK001582 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="239" pm="."><plain>3 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="240" pm="."><plain>89,485,137 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="241" pm="."><plain>89,499,861 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="242" pm="."><plain>loss </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="243" pm="."><plain>r </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="244" pm="."><plain>2 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="245" pm="."><plain>1.75 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="246" pm="."><plain>11 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="247" pm="."><plain>10.38 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="248" pm="."><plain>0.0065024 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="249" pm="."><plain>EPHA3 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="250" pm="."><plain>EPH receptor A3 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="251" pm="."><plain>2 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="252" pm="."><plain>208,064,053 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="253" pm="."><plain>208,066,082 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="254" pm="."><plain>loss </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="255" pm="."><plain>r </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="256" pm="."><plain>2 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="257" pm="."><plain>1.75 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="258" pm="."><plain>11 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="259" pm="."><plain>10.38 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="260" pm="."><plain>0.0065024 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="261" pm="."><plain>intergenic </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="262" pm="."><plain>1 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="263" pm="."><plain>97,830,032 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="264" pm="."><plain>97,841,389 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="265" pm="."><plain>gain </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="266" pm="."><plain>r </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="267" pm="."><plain>12 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="268" pm="."><plain>10.53 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="269" pm="."><plain>2 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="270" pm="."><plain>1.89 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="271" pm="."><plain>0.0076187 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="272" pm="."><plain>DPYD </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="273" pm="."><plain>dihydropyrimidine dehydrogenase </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="274" pm="."><plain>4 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="275" pm="."><plain>153,010,030 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="276" pm="."><plain>153,012,241 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="277" pm="."><plain>loss </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="278" pm="."><plain>r </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="279" pm="."><plain>12 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="280" pm="."><plain>10.53 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="281" pm="."><plain>2 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="282" pm="."><plain>1.89 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="283" pm="."><plain>0.0076187 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="284" pm="."><plain>intergenic </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="285" pm="."><plain>2 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="286" pm="."><plain>89,731,562 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="287" pm="."><plain>89,757,456 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="288" pm="."><plain>loss </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="289" pm="."><plain>r </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="290" pm="."><plain>6 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="291" pm="."><plain>5.26 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="292" pm="."><plain>0 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="293" pm="."><plain>0.00 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="294" pm="."><plain>0.0181413 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="295" pm="."><plain>near centromeric region </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="296" pm="."><plain>1 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="297" pm="."><plain>147456822 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="298" pm="."><plain>147655013 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="299" pm="."><plain>loss </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="300" pm="."><plain>r </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="301" pm="."><plain>17 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="302" pm="."><plain>14.91 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="303" pm="."><plain>6 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="304" pm="."><plain>5.66 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="305" pm="."><plain>0.0203443 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="306" pm="."><plain>NBPF20 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="307" pm="."><plain>neuroblastoma breakpoint family, member 20 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="308" pm="."><plain>7 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="309" pm="."><plain>61,792,309 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="310" pm="."><plain>61,797,361 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="311" pm="."><plain>loss </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="312" pm="."><plain>r </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="313" pm="."><plain>12 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="314" pm="."><plain>10.53 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="315" pm="."><plain>3 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="316" pm="."><plain>2.83 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="317" pm="."><plain>0.0208864 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="318" pm="."><plain>near centromeric region </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="319" pm="."><plain>11 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="320" pm="."><plain>107,166,452 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="321" pm="."><plain>107,175,438 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="322" pm="."><plain>gain </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="323" pm="."><plain>r </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="324" pm="."><plain>8 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="325" pm="."><plain>7.02 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="326" pm="."><plain>1 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="327" pm="."><plain>0.94 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="328" pm="."><plain>0.022996 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="329" pm="."><plain>SLC35F2 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="330" pm="."><plain>solute carrier family 35, member F2 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="331" pm="."><plain>13 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="332" pm="."><plain>63,241,820 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="333" pm="."><plain>63,285,508 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="334" pm="."><plain>gain </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="335" pm="."><plain>r </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="336" pm="."><plain>8 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="337" pm="."><plain>7.02 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="338" pm="."><plain>1 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="339" pm="."><plain>0.94 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="340" pm="."><plain>0.022996 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="341" pm="."><plain>AK127969 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="342" pm="."><plain>uncharacterized protein FLJ25694 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="343" pm="."><plain>6 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="344" pm="."><plain>62,237,262 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="345" pm="."><plain>62,247,872 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="346" pm="."><plain>loss </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="347" pm="."><plain>r </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="348" pm="."><plain>13 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="349" pm="."><plain>11.40 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="350" pm="."><plain>4 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="351" pm="."><plain>3.77 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="352" pm="."><plain>0.0292191 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="353" pm="."><plain>intergenic </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="354" pm="."><plain>3 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="355" pm="."><plain>190,847,117 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="356" pm="."><plain>190,849,456 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="357" pm="."><plain>loss </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="358" pm="."><plain>r </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="359" pm="."><plain>6 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="360" pm="."><plain>5.26 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="361" pm="."><plain>14 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="362" pm="."><plain>13.21 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="363" pm="."><plain>0.034200 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="364" pm="."><plain>TP63 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="365" pm="."><plain>tumor protein p63 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="366" pm="."><plain>12 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="367" pm="."><plain>58,222,193 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="368" pm="."><plain>58,228,389 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="369" pm="."><plain>loss </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="370" pm="."><plain>r </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="371" pm="."><plain>23 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="372" pm="."><plain>20.18 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="373" pm="."><plain>11 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="374" pm="."><plain>10.38 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="375" pm="."><plain>0.0333527 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="376" pm="."><plain>intergenic </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="377" pm="."><plain>15 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="378" pm="."><plain>54,580,082 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="379" pm="."><plain>54,588,851 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="380" pm="."><plain>loss </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="381" pm="."><plain>r </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="382" pm="."><plain>1 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="383" pm="."><plain>0.88 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="384" pm="."><plain>6 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="385" pm="."><plain>5.66 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="386" pm="."><plain>0.0486939 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="387" pm="."><plain>intergenic </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="388" pm="."><plain>8 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="389" pm="."><plain>47,647,579 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="390" pm="."><plain>47,654,762 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="391" pm="."><plain>gain </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="392" pm="."><plain>r </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="393" pm="."><plain>1 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="394" pm="."><plain>0.88 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="395" pm="."><plain>6 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="396" pm="."><plain>5.66 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="397" pm="."><plain>0.0486939 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="398" pm="."><plain>intergenic </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt101"><label/><p><text><SENT sid="399" pm="."><plain>loss* Homozygous deletion. </plain></SENT>
</text></p></fn></table-wrap-foot></table-wrap></SecTag><p><text><SENT sid="400" pm="."><plain>As compiled in Table 3, the most significant association was shown for a 41 kb intergenic heterozygous deletion (chr11: 50,545,009–50,586,426) in the proximity of the centromere. </plain></SENT>
<SENT sid="401" pm="."><plain>This intergenic deletion was observed in 18.26% of patients and 1.89% of controls (p = 3.23×10−5), thus conferring approximately 10-fold increased risk for ALS. </plain></SENT>
<SENT sid="402" pm="."><plain>The second most significant CNV association was detected for another intergenic 15 kb heterozygous deletion (Chr19: 20,860,930–20,875,787). </plain></SENT>
<SENT sid="403" pm="."><plain>This previously reported deletion was observed in 13.16% of patients and 1.89% of controls, also conferring increased ALS risk (p = 0.00132) (Figure S1). </plain></SENT>
</text></p><p><text><SENT sid="404" pm="."><plain>CNVs in coding regions of the MAP4K3, HLA-B (major histocompatibility complex, class I, B), EPHA3 (EPH receptor A3) and DPYD (dihydropyrimidine dehydrogenase) genes were also found to be associated with ALS risk orprotection. </plain></SENT>
<SENT sid="405" pm="."><plain>The novel 56,472 bp duplication, covering both exonic and intronic parts of MAP4K3 (chr2: 39,372,016–39,428,488), was observed in 12.17% of cases and in only 1.89% of controls, thus conferring significantly increased ALS risk (p = 0.0025). </plain></SENT>
<SENT sid="406" pm="."><plain>The second candidate, an 11.5 kb duplication in the coding region of DPYD, was also significantly associated with ALS (p = 0.008, detected in 10.5% of ALS patients and 2% of controls). </plain></SENT>
<SENT sid="407" pm="."><plain>In addition, a 4 kb homozygous deletion (chr6: 31,389,749–31,393,270) in the intronic part of the HLA-B gene was observed in 7% ALS patients and was absent in controls (p = 0.0046). </plain></SENT>
<SENT sid="408" pm="."><plain>As opposed to the above loci, a 14 kb heterozygous deletion, spanning both the exonic and intronic parts of EPHA3 (chr3: 89,485,137–89,499,861) was found to be significantly protective for ALS, present in ∼10% of controls and only 2% of ALS patients (p = 0.0062) (Table 3) (Figure S1). </plain></SENT>
<SENT sid="409" pm="."><plain>This locus was previously identified in several studies on healthy individuals [14], [15]. </plain></SENT>
</text></p></sec><sec id="s3d"><title><text><SENT sid="410" pm="."><plain>Rare CNVs </plain></SENT>
</text></title><p><text><SENT sid="411" pm="."><plain>Although statistically not significant, ∼15 rare CNV regions (with less than 5% frequency in cases or controls) were also detected in this study. </plain></SENT>
<SENT sid="412" pm="."><plain>Among these, eight represented gains, whereas seven were losses, including six heterozygous deletions and a homozygous intergenic deletion. </plain></SENT>
<SENT sid="413" pm="."><plain>Some of those were ALS-specific and others were control-specific. </plain></SENT>
<SENT sid="414" pm="."><plain>The top candidates in coding regions included the novel CNV loci in ACYP2 (acylphosphatase 2, muscle type), LPHN3 (latrophilin 3) and TAC1 (tachykinin, precursor 1) genes (Table 4). </plain></SENT>
<SENT sid="415" pm="."><plain>Besides rare CNVs, approximately 500 CNV calls were individual-specific (private). </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="pone-0072381-t004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0072381.t004</object-id><label>Table 4</label><caption><title><text><SENT sid="416" pm="."><plain>Rare CNVs observed in analysis. </plain></SENT>
</text></title></caption><alternatives><graphic id="pone-0072381-t004-4" xlink:href="pone.0072381.t004"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="417" pm="."><plain>Chr </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="418" pm="."><plain>Start (bp) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="419" pm="."><plain>End (bp) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="420" pm="."><plain>Change </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="421" pm="."><plain>Novel/reported </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="422" pm="."><plain>ALS </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="423" pm="."><plain>% </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="424" pm="."><plain>Control </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="425" pm="."><plain>% </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="426" pm="."><plain>Intergenic/Gene region </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="427" pm="."><plain>Gene Name </plain></SENT>
</text></td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="428" pm="."><plain>2 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="429" pm="."><plain>54,343,530 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="430" pm="."><plain>54,356,415 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="431" pm="."><plain>loss </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="432" pm="."><plain>n </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="433" pm="."><plain>4 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="434" pm="."><plain>3.51 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="435" pm="."><plain>0 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="436" pm="."><plain>0.00 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="437" pm="."><plain>ACYP2 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="438" pm="."><plain>acylphosphatase 2, muscle type </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="439" pm="."><plain>4 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="440" pm="."><plain>62,506,258 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="441" pm="."><plain>62,566,026 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="442" pm="."><plain>gain </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="443" pm="."><plain>n </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="444" pm="."><plain>4 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="445" pm="."><plain>3.51 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="446" pm="."><plain>0 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="447" pm="."><plain>0.00 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="448" pm="."><plain>LPHN3 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="449" pm="."><plain>latrophilin 3 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="450" pm="."><plain>6 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="451" pm="."><plain>19,153,539 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="452" pm="."><plain>19,156,752 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="453" pm="."><plain>loss* </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="454" pm="."><plain>r </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="455" pm="."><plain>4 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="456" pm="."><plain>3.51 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="457" pm="."><plain>0 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="458" pm="."><plain>0.00 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="459" pm="."><plain>intergenic </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="460" pm="."><plain>8 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="461" pm="."><plain>2,798,648 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="462" pm="."><plain>2,815,064 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="463" pm="."><plain>gain </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="464" pm="."><plain>r </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="465" pm="."><plain>4 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="466" pm="."><plain>3.51 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="467" pm="."><plain>0 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="468" pm="."><plain>0.00 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="469" pm="."><plain>CSMD1 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="470" pm="."><plain>CUB and Sushi multiple domains 1 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="471" pm="."><plain>20 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="472" pm="."><plain>61,791,411 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="473" pm="."><plain>61,844,885 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="474" pm="."><plain>gain </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="475" pm="."><plain>r </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="476" pm="."><plain>4 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="477" pm="."><plain>3.51 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="478" pm="."><plain>0 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="479" pm="."><plain>0.00 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="480" pm="."><plain>RTEL1 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="481" pm="."><plain>regulator of telomere elongation helicase 1 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="482" pm="."><plain>1 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="483" pm="."><plain>116,197,766 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="484" pm="."><plain>116,202,917 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="485" pm="."><plain>loss </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="486" pm="."><plain>r </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="487" pm="."><plain>0 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="488" pm="."><plain>0.00 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="489" pm="."><plain>2 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="490" pm="."><plain>1.89 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="491" pm="."><plain>intergenic </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="492" pm="."><plain>1 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="493" pm="."><plain>150,519,809 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="494" pm="."><plain>150,526,366 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="495" pm="."><plain>loss </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="496" pm="."><plain>n </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="497" pm="."><plain>0 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="498" pm="."><plain>0.00 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="499" pm="."><plain>4 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="500" pm="."><plain>3.77 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="501" pm="."><plain>intergenic </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="502" pm="."><plain>3 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="503" pm="."><plain>150,447,382 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="504" pm="."><plain>150,450,025 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="505" pm="."><plain>loss </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="506" pm="."><plain>r </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="507" pm="."><plain>0 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="508" pm="."><plain>0.00 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="509" pm="."><plain>3 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="510" pm="."><plain>2.83 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="511" pm="."><plain>intergenic </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="512" pm="."><plain>3 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="513" pm="."><plain>156,963,791 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="514" pm="."><plain>156,988,291 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="515" pm="."><plain>gain </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="516" pm="."><plain>r </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="517" pm="."><plain>0 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="518" pm="."><plain>0.00 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="519" pm="."><plain>3 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="520" pm="."><plain>2.83 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="521" pm="."><plain>C3orf33 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="522" pm="."><plain>chromosome 3 open reading frame 33 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="523" pm="."><plain>3 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="524" pm="."><plain>163,637,770 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="525" pm="."><plain>163,690,547 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="526" pm="."><plain>gain </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="527" pm="."><plain>n </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="528" pm="."><plain>0 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="529" pm="."><plain>0.00 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="530" pm="."><plain>5 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="531" pm="."><plain>4.72 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="532" pm="."><plain>intergenic </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="533" pm="."><plain>7 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="534" pm="."><plain>97,203,867 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="535" pm="."><plain>97,226,966 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="536" pm="."><plain>gain </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="537" pm="."><plain>n </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="538" pm="."><plain>4 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="539" pm="."><plain>3.51 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="540" pm="."><plain>0 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="541" pm="."><plain>0.00 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="542" pm="."><plain>TAC1 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="543" pm="."><plain>tachykinin, precursor 1 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="544" pm="."><plain>8 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="545" pm="."><plain>70,595,842 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="546" pm="."><plain>70,622,357 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="547" pm="."><plain>gain </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="548" pm="."><plain>r </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="549" pm="."><plain>4 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="550" pm="."><plain>3.51 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="551" pm="."><plain>0 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="552" pm="."><plain>0.00 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="553" pm="."><plain>SULF1 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="554" pm="."><plain>sulfatase 1 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="555" pm="."><plain>9 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="556" pm="."><plain>71,289,938 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="557" pm="."><plain>71,305,531 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="558" pm="."><plain>loss </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="559" pm="."><plain>r </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="560" pm="."><plain>3 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="561" pm="."><plain>2.63 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="562" pm="."><plain>0 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="563" pm="."><plain>0.00 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="564" pm="."><plain>APBA1 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="565" pm="."><plain>amyloid beta (A4) precursor protein-binding, family A, member 1 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="566" pm="."><plain>9 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="567" pm="."><plain>138,380,284 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="568" pm="."><plain>138,416,305 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="569" pm="."><plain>gain </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="570" pm="."><plain>r </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="571" pm="."><plain>0 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="572" pm="."><plain>0.00 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="573" pm="."><plain>4 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="574" pm="."><plain>3.77 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="575" pm="."><plain>CARD9 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="576" pm="."><plain>caspase recruitment domain family, member 9 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="577" pm="."><plain>10 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="578" pm="."><plain>58,574,865 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="579" pm="."><plain>58,606,945 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="580" pm="."><plain>loss </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="581" pm="."><plain>r </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="582" pm="."><plain>0 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="583" pm="."><plain>0.00 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="584" pm="."><plain>4 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="585" pm="."><plain>3.77 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="586" pm="."><plain>intergenic </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt102"><label/><p><text><SENT sid="587" pm="."><plain>loss* Homozygous deletion. </plain></SENT>
</text></p></fn></table-wrap-foot></table-wrap></SecTag></sec><sec id="s3e"><title><text><SENT sid="588" pm="."><plain>CNV Call Validation Using LRR Values </plain></SENT>
</text></title><p><text><SENT sid="589" pm="."><plain>Top significant CNV loci indicated by PennCNV were also investigated by plotting SNP data of all individuals (Figure S2). </plain></SENT>
<SENT sid="590" pm="."><plain>Average LRR values of SNPs in top candidate CNV loci were analyzed. </plain></SENT>
<SENT sid="591" pm="."><plain>In four distinct locations, changes in the intergenic region on chromosome 11, MAP4K3, HLA-B and EPHA3 genes including their proximity regions from both ends were found to be significant. </plain></SENT>
<SENT sid="592" pm="."><plain>The difference in LRRs of SNPs was observed in CNV regions of loss of intergenic region on chr11 and gain of MAP4K3 gene, loss of HLA-B and EPHA3 genes. </plain></SENT>
<SENT sid="593" pm="."><plain>Unlike CNV regions, upstream and downstream sequences of these regions did not show any significant change (Figure 1). </plain></SENT>
<SENT sid="594" pm="."><plain>Other top candidate CNV loci including intergenic loci, DPYD, NBPF20, SLC35F2 and TP63 were not found to be significant according to LRR validation. </plain></SENT>
</text></p><SecTag type="FIG"><fig id="pone-0072381-g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0072381.g001</object-id><label>Figure 1</label><caption><title><text><SENT sid="595" pm="."><plain>CNV call validation via LRR values. </plain></SENT>
</text></title><p><text><SENT sid="596" pm="."><plain>LRR values of controls and individuals with CNV for particular SNPs were extracted to check CNV calls of PennCNV tool. </plain></SENT>
<SENT sid="597" pm="."><plain>Average LRR values of each SNP for both groups were calculated and plotted. </plain></SENT>
<SENT sid="598" pm="."><plain>Consecutive SNPs in chromosome position line do not demonstrate the exact distance. </plain></SENT>
<SENT sid="599" pm="."><plain>The CNVs detected by PennCNV were shown by black bars. </plain></SENT>
<SENT sid="600" pm="."><plain>(a) Loss of an intergenic region on chromosome 11 between rs1916207 and rs554110 (chr11: 50,545,009–50,586,426), (b) gain of MAP4K3 gene between rs12151392 and rs2373530 (chr2: 39,372,016–39,428,488), (c) homozygous loss of HLA-B gene between rs9295976 and rs28367708 (chr6: 31,389,749–31,393,270), (d) loss of EPHA3 gene between rs2063589 and rs870899 (chr3: 89,485,137–89,499,861) (NCBI37/hg19). </plain></SENT>
</text></p></caption><graphic xlink:href="pone.0072381.g001"/></fig></SecTag><p><text><SENT sid="601" pm="."><plain>To validate the CNV loci predicted, LRR values of these individuals (the intensities of controls and individuals with CNV, obtained from the array) at a particular SNP were analyzed for each CNV region, including chromosome 11, MAP4K3, HLA-B and EPHA3 genes (Figure 2). </plain></SENT>
<SENT sid="602" pm="."><plain>rs1411423 and rs2133209, located nearby the intergenic CNV region of chr11, did not show any intensity changes in any individual, whereas lower intensity changes were observed in individuals with CNV at rs10902001 and rs2313927 (located within the CNV loci) compared to controls. </plain></SENT>
<SENT sid="603" pm="."><plain>These differences were highly significant (p&lt;0.0005) (Figure 2a). </plain></SENT>
<SENT sid="604" pm="."><plain>In MAP4K3 gene region, LRRs of SNPs (rs17023552 and rs6712399) nearby the CNV loci did not display any difference, on the other hand SNPs located within the CNV loci showed significant changes (p&lt;0.0005). </plain></SENT>
<SENT sid="605" pm="."><plain>Higher intensities were observed in individuals with CNV indicating duplication (Figure 2b). </plain></SENT>
<SENT sid="606" pm="."><plain>In HLA-B region, very low insenties were obtained in individuals with CNV when compared to controls. </plain></SENT>
<SENT sid="607" pm="."><plain>Intensities of controls were normal at each SNP, however, lower intensities at rs9295975 and rs28367780 and a slight increase were seen at rs9265664 (Figure 2c). </plain></SENT>
<SENT sid="608" pm="."><plain>Like HLA-B, at SNPs, rs9866959 and rs7636790, located upstream and downstream of the CNV region, intensities were almost the same. </plain></SENT>
<SENT sid="609" pm="."><plain>Within the CNV regions, lower intensities were observed significantly in individuals with above CNV (Figure 2d). </plain></SENT>
</text></p><SecTag type="FIG"><fig id="pone-0072381-g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0072381.g002</object-id><label>Figure 2</label><caption><title><text><SENT sid="610" pm="."><plain>Distribution of LRR values of controls and individuals with CNV at SNP level. </plain></SENT>
</text></title><p><text><SENT sid="611" pm="."><plain>LRRs of all individuals were extracted and plotted. “Cont” indicates control individuals and “CNV” indicates individuals with a CNV. “*” indicates the significance level between controls and CNV. </plain></SENT>
<SENT sid="612" pm="."><plain>4 SNPs, including one upstream, one downstream and two within the CNV region, were selected and LRRs were plotted for (a) intergenic reigon on chromosome 11, (b) MAP4K3 gene, (c) HLA-B gene and (d) EPHA3 gene. </plain></SENT>
</text></p></caption><graphic xlink:href="pone.0072381.g002"/></fig></SecTag></sec><sec id="s3f"><title><text><SENT sid="613" pm="."><plain>Validation of CNV Calls Using Quantitative PCR </plain></SENT>
</text></title><p><text><SENT sid="614" pm="."><plain>Among the top candidates, the gene containing loci (MAP4K3, HLA-B and EPHA3), which were validated by LRR values were further subjected to TaqMan CNV detection analysis. </plain></SENT>
<SENT sid="615" pm="."><plain>The PennCNV results of MAP4K3 and HLA-B, were not validated and thus concluded as false positives. </plain></SENT>
<SENT sid="616" pm="."><plain>For MAP4K3, the cases shown to have one extra copy by PennCNV, were found to have two copies of the CNV. </plain></SENT>
<SENT sid="617" pm="."><plain>On the other hand, one control sample which was shown to have two copies by PennCNV, had one copy of the CNV in the MAP4K3 locus (Figure S3a). </plain></SENT>
<SENT sid="618" pm="."><plain>Similarly, HLA-B results were not validated in eight ALS patients, found to have deletions according to PennCNV, however, heterozygous deletions were found in other controls and ALS patients who were shown to have two copies by PennCNV (Figure S3b).As opposed to the above results, for the EPHA3 locus, two ALS patients and 11 healthy controls with deletions were validated by TaqMan CNV assay. </plain></SENT>
<SENT sid="619" pm="."><plain>All other individuals seven ALS and seven controls harboring two copies according to the PennCNV results, were found to be in accordance (Figure S3c). </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="DISCUSS"><sec id="s4"><title><text><SENT sid="620" pm="."><plain>Discussion </plain></SENT>
</text></title><p><text><SENT sid="621" pm="."><plain>In this study, we have carried out, for the first time, a CNV analysis in a Turkish ALS cohort of 117 ALS patients and 109 controls (GWAS data available upon request). </plain></SENT>
<SENT sid="622" pm="."><plain>After validation analyses, EPHA3 was shown to be a potential protective factor for ALS. </plain></SENT>
</text></p><p><text><SENT sid="623" pm="."><plain>Common and rare genetic variants like SNPs and CNVs may contribute to complex disease development. </plain></SENT>
<SENT sid="624" pm="."><plain>Candidate SNPs in several genes, including DPP6, ITPR2, KIFAP3 and UNC13A, were previously shown to be associated with ALS using the GWAS platform although the contribution of these SNPs to disease pathogenesis remained questionable in different studies [18], [19], [20], [21]. </plain></SENT>
<SENT sid="625" pm="."><plain>The more recently discovered CNVs, on the other hand, are also abundant and dynamic throughout the genome and they can cause genetic variations even between two closely related individuals. </plain></SENT>
<SENT sid="626" pm="."><plain>Because of their much larger sizes, CNVs may have more drastic effects on the human genome, thus on complex disease development in humans. [22]. </plain></SENT>
</text></p><p><text><SENT sid="627" pm="."><plain>Our findings are not in complete accordance with similar studies performed in European and US-Eurepean populations; this may be on one hand due to our relatively small sample size and on the other hand due to the general discordance between GWAS/CNV studies performed so far. </plain></SENT>
<SENT sid="628" pm="."><plain>Very importantly, the differences may also be population-specific. </plain></SENT>
<SENT sid="629" pm="."><plain>Considering the great ethnic heterogeneity of the Turkish population, to confirm our findings, CNV analysis has to be expanded to a larger and independent Turkish cohort; a very well-characterized and well-matched cohort is required for unbiased results in a heterogeneous population. </plain></SENT>
</text></p><p><text><SENT sid="630" pm="."><plain>Rare CNVs have been observed in some patients and controls, including several gene regions, e.g. ACYP2, LPHN3, CSMD1, RTEL1, TAC1, SULF1 and APBA1. </plain></SENT>
<SENT sid="631" pm="."><plain>None of them has been associated with ALS before. </plain></SENT>
<SENT sid="632" pm="."><plain>In this study, the CNVs in the ACYP2 and LPHN3 gene regions are novel and they were not found in our control populations, thus would be classified as promising risk-conferring candidates. </plain></SENT>
<SENT sid="633" pm="."><plain>The remaining CNVs were all reported in DGV. </plain></SENT>
<SENT sid="634" pm="."><plain>Four ALS patients in the study cohort had a novel CNV deletion in heterozygous form in the ACYP2 gene. </plain></SENT>
<SENT sid="635" pm="."><plain>This enzyme family which acts as a phosphatase, serves particularly to modulate Ca+2 from the endoplasmic reticulum; like ITPR2 shown to be a risk factor in ALS [20], [23]. </plain></SENT>
<SENT sid="636" pm="."><plain>All of our ALS patients had a relatively early age of onset (32–44), three with limb and one with bulbar initiation. </plain></SENT>
<SENT sid="637" pm="."><plain>When statistical analysis was applied, rare CNVs, including the most promising ACYP2, were found to be non-significant, as expected, but this does not conclude that their effects are not considerable, only their presence is limited. </plain></SENT>
<SENT sid="638" pm="."><plain>Their loss cannot be pathogenic and would not cause toxicity, however this loss may protect cell from stress. </plain></SENT>
<SENT sid="639" pm="."><plain>To understand rare and novel CNVs and their contributions to complex disease development, further investigation of these CNVs in terms of their functions in the cell, their involvement in cellular pathways and their association with other diseases are necessary. </plain></SENT>
</text></p><p><text><SENT sid="640" pm="."><plain>The most significant CNV, conferring highly increased risk to ALS in our cohort, is the previously described 41 kb-long centromeric heterozygous deletion at the 11p11.12 locus [17]. </plain></SENT>
<SENT sid="641" pm="."><plain>Although there are no coding genes detected in proximal regions of this candidate locus, there are several transcription factor binding sites. </plain></SENT>
<SENT sid="642" pm="."><plain>Presence of deletions or duplications in this region may alter arrangements of chromosomal and centromeric parts in this locus. </plain></SENT>
<SENT sid="643" pm="."><plain>Furthermore, deletions found at 11p11.12 have been implicated in several cancer types and also in the Potocki-Shaffer syndrome [24], [25], [26]. </plain></SENT>
<SENT sid="644" pm="."><plain>The risk-conferring nature of this locus has to be validated by further genotyping assays. </plain></SENT>
</text></p><p><text><SENT sid="645" pm="."><plain>MAP4K3 has multiple functions in signal transduction of mammalian cells, such as activation of the JNK pathway and regulation of TORC1 signaling. </plain></SENT>
<SENT sid="646" pm="."><plain>Increased synthesis of the protein due to duplication may result in excess protein through the TORC1 pathway, leading to ER stress and misfolded protein response which are important mechanisms of ALS pathology. </plain></SENT>
<SENT sid="647" pm="."><plain>PennCNV found a novel significant duplication at the MAP4K3 locus and also intensities (LRR) for MAP4K3 were significant (Figure 2), however, TaqMan CNV genotyping did not confirm the PennCNV results in this cohort. </plain></SENT>
<SENT sid="648" pm="."><plain>CNVs at HLA-B locus have been reported previously [15], [17] and many HLA genes were found to be associated with several diseases, such as multiple sclerosis [27], [28]. </plain></SENT>
<SENT sid="649" pm="."><plain>A homozygous deletion at the HLA-B locus found by PennCNV failed to be validated after qPCR. </plain></SENT>
<SENT sid="650" pm="."><plain>One reason for this failure may be the highly polymorphic structure of HLAs in humans, possibly resulting in different outcomes in GWAS. </plain></SENT>
<SENT sid="651" pm="."><plain>Upon the results of TaqMan genotyping, the CNVs detected by PennCNV in MAP4K3 and HLA-B were classified as false-positives. </plain></SENT>
</text></p><p><text><SENT sid="652" pm="."><plain>Another candidate gene detected by PennCNV analysis was Epha3, shown to be a protective factor for ALS. </plain></SENT>
<SENT sid="653" pm="."><plain>Most importantly, validation analysis by qPCR confirmed this result. </plain></SENT>
<SENT sid="654" pm="."><plain>Ephrin (Eph) receptors are the largest known protein subfamily of receptor tyrosine kinases. </plain></SENT>
<SENT sid="655" pm="."><plain>This protein family consists of 14 members in A and B subgroups. </plain></SENT>
<SENT sid="656" pm="."><plain>Ephrin receptors and ligands enable cell to cell interactions. </plain></SENT>
<SENT sid="657" pm="."><plain>Their signaling also regulates processes during embryonic development, such as neuronal cell migration, vasculogenesis and axon guidance [29]. </plain></SENT>
<SENT sid="658" pm="."><plain>We observed that deletion of one copy of EPHA3 is significantly higher in controls as compared to ALS patients (p = 0.0065024). </plain></SENT>
<SENT sid="659" pm="."><plain>In line with this result, in 2012, van Hoecke et al. reported that EPHA4, one of Ephs, to be a disease-modifier of ALS. </plain></SENT>
<SENT sid="660" pm="."><plain>Loss of function mutation and knock-down of EPHA4 gene in mutant SOD1 phenotype rescues and enables long survival [30], indicating a protective effect of EPHA4 gene on disease progression. </plain></SENT>
<SENT sid="661" pm="."><plain>This indicates that Ephs can be protective targets in ALS for therapeutic intervention. </plain></SENT>
</text></p><p><text><SENT sid="662" pm="."><plain>ALS is a complex neurodegenerative disease, with both upper and lower motor neuron involvement. </plain></SENT>
<SENT sid="663" pm="."><plain>Although the average age of onset is 50–60 years and the average survival around three years, variability in disease initiation and duration vary tremendously. </plain></SENT>
<SENT sid="664" pm="."><plain>Even manifestation of the disease in affected family members with the same mutation and in the same gene may be variable from complete to restricted penetrance. </plain></SENT>
<SENT sid="665" pm="."><plain>Genetic modifying factors are thought to underlie this variability; identification of such modifying pathways is of interest as they may be target for therapeutic interventions. </plain></SENT>
<SENT sid="666" pm="."><plain>This study represents a sound effort to enlarge our knowledge about ALS risk genes through a genome-wide copy number variation screen in the Turkish population. </plain></SENT>
<SENT sid="667" pm="."><plain>We hope that its novel findings will contribute to the understanding of the complex pathways leading to neurodegeneration and ALS. </plain></SENT>
</text></p></sec></SecTag><SecTag type="SUPPL"><sec sec-type="supplementary-material" id="s5"><title><text><SENT sid="668" pm="."><plain>Supporting Information </plain></SENT>
</text></title><supplementary-material content-type="local-data" id="pone.0072381.s001"><label>Figure S1</label><caption><p><text><SENT sid="669" pm="."><plain>CNVs detected in ALS patients and controls by PennCNV tool were plotted using University of California Santa Cruz (UCSC) Genome Browser ( <ext-link ext-link-type="uri" xlink:href="http://genome.ucsc.edu/">http://genome.ucsc.edu/</ext-link>). </plain></SENT>
<SENT sid="670" pm="."><plain>(a). </plain></SENT>
<SENT sid="671" pm="."><plain>Deletion in centromeric region. </plain></SENT>
<SENT sid="672" pm="."><plain>Chr11: 50,545,009–50,586,426, (b) Deletion in intergenic region. </plain></SENT>
<SENT sid="673" pm="."><plain>Chr19: 20,860,930–20,875,787, (c) Duplication in MAP4K3 gene. </plain></SENT>
<SENT sid="674" pm="."><plain>Chr2: 39,372,016–39,428,488, (d) Homozygous deletion in HLA-B gene. </plain></SENT>
<SENT sid="675" pm="."><plain>Chr6: 31,389,749–31,393,270 (e) Deletion in EPHA3 gene. </plain></SENT>
<SENT sid="676" pm="."><plain>Chr3: 89,485,137–89,499,861 (f) Duplication in DPYD gene. </plain></SENT>
<SENT sid="677" pm="."><plain>Chr1: 97,830,032–97,841,389. </plain></SENT>
</text></p><p><text><SENT sid="678" pm="."><plain>(DOCX) </plain></SENT>
</text></p></caption><media xlink:href="pone.0072381.s001.docx"><caption><p><text><SENT sid="679" pm="."><plain>Click here for additional data file. </plain></SENT>
</text></p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0072381.s002"><label>Figure S2</label><caption><p><text><SENT sid="680" pm="."><plain>Plotting CNV calls of patients and control samples using signal intensities by PennCNV. </plain></SENT>
<SENT sid="681" pm="."><plain>Each dot represents its Log R Ratio and B Allele Frequency of a SNP. </plain></SENT>
<SENT sid="682" pm="."><plain>Red indicates SNPs in the CNV site, blue represents SNPs neighboring the CNV region. (a) ALS-274 and Control-329 have one copy deletion (CN = 1) on chromosome 11, between positions 50.4 Mb and 51.1 Mb. </plain></SENT>
<SENT sid="683" pm="."><plain>(b) ALS-283 and Control-533 have one copy duplication (CN = 3) on chromosome 1, between positions 97.83 Mb and 97.85 Mb. </plain></SENT>
<SENT sid="684" pm="."><plain>(c) ALS-51 and ALS-106 have one copy deletion (CN = 1) on chromosome 2, between positions 54.2 Mb and 54.37 Mb. </plain></SENT>
</text></p><p><text><SENT sid="685" pm="."><plain>(DOCX) </plain></SENT>
</text></p></caption><media xlink:href="pone.0072381.s002.docx"><caption><p><text><SENT sid="686" pm="."><plain>Click here for additional data file. </plain></SENT>
</text></p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0072381.s003"><label>Figure S3</label><caption><p><text><SENT sid="687" pm="."><plain>TaqMan CNV Assay results of MAP4K3, HLA-B and EPHA3 genes. Screen shots taken from the CopyCaller software. </plain></SENT>
<SENT sid="688" pm="."><plain>(a) Dark Blue samples which were found by PennCNV as candidates to have higher copy number of MAP4K3 gene (n = 3). </plain></SENT>
<SENT sid="689" pm="."><plain>Light blue samples were supposed to have normal copy number (n = 2). </plain></SENT>
<SENT sid="690" pm="."><plain>(b) Dark Blue samples which were found by PennCNV as candidates to have no copy number of HLA-B gene (n = 0). </plain></SENT>
<SENT sid="691" pm="."><plain>Light blue samples were supposed to have normal copy number (n = 2). </plain></SENT>
<SENT sid="692" pm="."><plain>(c) Dark Blue samples which were found by PennCNV as candidates to have single copy number of EPHA3 gene (n = 1). </plain></SENT>
<SENT sid="693" pm="."><plain>Light blue samples were supposed to have normal copy number (n = 2). </plain></SENT>
<SENT sid="694" pm="."><plain>C462 and C672 control samples were supposed to have single copy numbers, however, they had no copy numbers of EPHA3 (n = 0). </plain></SENT>
</text></p><p><text><SENT sid="695" pm="."><plain>(DOCX) </plain></SENT>
</text></p></caption><media xlink:href="pone.0072381.s003.docx"><caption><p><text><SENT sid="696" pm="."><plain>Click here for additional data file. </plain></SENT>
</text></p></caption></media></supplementary-material></sec></SecTag></body><back><SecTag type="ACK_FUND"><ack><p><text4fund><text><SENT sid="697" pm="."><plain>We would like to acknowledge the technical assistance of Zeynep Itah, Nesli Ece Şen, Ceren Iskender, Uğur Tüfekci, Evrim Bilgin and Alireza K. Jamayran. </plain></SENT>
<SENT sid="699" pm="."><plain>Also we would like to thank Mehran Meschian, Luis Antonio Mendoza Martinez and Yongmei Ding for data management. </plain></SENT>
<SENT sid="700" pm="."><plain>This study is dedicated to the memory of our esteemed collaborator Dr. Hilmi Özçelik who passed away on April 2, 2013. </plain></SENT>
</text></text4fund></p></ack></SecTag><SecTag type="REF"><ref-list><title>References</title><ref id="pone.0072381-Pasinelli1"><text><SENT sid="701" pm="."><plain>1 PasinelliP, BrownRH (2006) Molecular biology of amyotrophic lateral sclerosis: insights from genetics. Nat Rev Neurosci 7: 710–723.16924260 </plain></SENT>
</text></ref><ref id="pone.0072381-Cronin1"><text><SENT sid="702" pm="."><plain>2 CroninS, BlauwHM, VeldinkJH, van EsMA, OphoffRA, et al (2008) Analysis of genome-wide copy number variation in Irish and Dutch ALS populations. Hum Mol Genet 17: 3392–3398.18689356 </plain></SENT>
</text></ref><ref id="pone.0072381-Blauw1"><text><SENT sid="703" pm="."><plain>3 BlauwHM, VeldinkJH, van EsMA, van VughtPW, SarisCG, et al (2008) Copy-number variation in sporadic amyotrophic lateral sclerosis: a genome-wide screen. Lancet Neurol 7: 319–326.18313986 </plain></SENT>
</text></ref><ref id="pone.0072381-Wain1"><text><SENT sid="704" pm="."><plain>4 WainLV, PedrosoI, LandersJE, BreenG, ShawCE, et al (2009) The role of copy number variation in susceptibility to amyotrophic lateral sclerosis: genome-wide association study and comparison with published loci. PLoS One 4: e8175.19997636 </plain></SENT>
</text></ref><ref id="pone.0072381-Blauw2"><text><SENT sid="705" pm="."><plain>5 BlauwHM, Al-ChalabiA, AndersenPM, van VughtPW, DiekstraFP, et al (2010) A large genome scan for rare CNVs in amyotrophic lateral sclerosis. Hum Mol Genet 19: 4091–4099.20685689 </plain></SENT>
</text></ref><ref id="pone.0072381-Blauw3"><text><SENT sid="706" pm="."><plain>6 BlauwHM, BarnesCP, van VughtPW, van RheenenW, VerheulM, et al (2012) SMN1 gene duplications are associated with sporadic ALS. Neurology 78: 776–780.22323753 </plain></SENT>
</text></ref><ref id="pone.0072381-Corcia1"><text><SENT sid="707" pm="."><plain>7 CorciaP, IngreC, BlascoH, PressR, PralineJ, et al (2012) Homozygous SMN2 deletion is a protective factor in the Swedish ALS population. Eur J Hum Genet 20: 588–591.22274580 </plain></SENT>
</text></ref><ref id="pone.0072381-Lahut1"><text><SENT sid="708" pm="."><plain>8 LahutS, OmurO, UyanO, AgimZS, OzoguzA, et al (2012) ATXN2 and its neighbouring gene SH2B3 are associated with increased ALS risk in the Turkish population. PLoS One 7: e42956.22916186 </plain></SENT>
</text></ref><ref id="pone.0072381-Brooks1"><text><SENT sid="709" pm="."><plain>9 BrooksBR, MillerRG, SwashM, MunsatTL (2000) El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 1: 293–299.11464847 </plain></SENT>
</text></ref><ref id="pone.0072381-Wang1"><text><SENT sid="710" pm="."><plain>10 WangK, LiM, HadleyD, LiuR, GlessnerJ, et al (2007) PennCNV: an integrated hidden Markov model designed for high-resolution copy number variation detection in whole-genome SNP genotyping data. Genome Res 17: 1665–1674.17921354 </plain></SENT>
</text></ref><ref id="pone.0072381-Ku1"><text><SENT sid="711" pm="."><plain>11 KuCS, PawitanY, SimX, OngRT, SeielstadM, et al (2010) Genomic copy number variations in three Southeast Asian populations. Hum Mutat 31: 851–857.20506136 </plain></SENT>
</text></ref><ref id="pone.0072381-Iafrate1"><text><SENT sid="712" pm="."><plain>12 IafrateAJ, FeukL, RiveraMN, ListewnikML, DonahoePK, et al (2004) Detection of large-scale variation in the human genome. Nat Genet 36: 949–951.15286789 </plain></SENT>
</text></ref><ref id="pone.0072381-Kent1"><text><SENT sid="713" pm="."><plain>13 KentWJ, SugnetCW, FureyTS, RoskinKM, PringleTH, et al (2002) The human genome browser at UCSC. Genome Res 12: 996–1006.12045153 </plain></SENT>
</text></ref><ref id="pone.0072381-Altshuler1"><text><SENT sid="714" pm="."><plain>14 AltshulerDM, GibbsRA, PeltonenL, DermitzakisE, SchaffnerSF, et al (2010) Integrating common and rare genetic variation in diverse human populations. Nature 467: 52–58.20811451 </plain></SENT>
</text></ref><ref id="pone.0072381-Conrad1"><text><SENT sid="715" pm="."><plain>15 ConradDF, PintoD, RedonR, FeukL, GokcumenO, et al (2010) Origins and functional impact of copy number variation in the human genome. Nature 464: 704–712.19812545 </plain></SENT>
</text></ref><ref id="pone.0072381-Matsuzaki1"><text><SENT sid="716" pm="."><plain>16 MatsuzakiH, WangPH, HuJ, RavaR, FuGK (2009) High resolution discovery and confirmation of copy number variants in 90 Yoruba Nigerians. Genome Biol 10: R125.19900272 </plain></SENT>
</text></ref><ref id="pone.0072381-Shaikh1"><text><SENT sid="717" pm="."><plain>17 ShaikhTH, GaiX, PerinJC, GlessnerJT, XieH, et al (2009) High-resolution mapping and analysis of copy number variations in the human genome: a data resource for clinical and research applications. Genome Res 19: 1682–1690.19592680 </plain></SENT>
</text></ref><ref id="pone.0072381-Cronin2"><text><SENT sid="718" pm="."><plain>18 CroninS, BergerS, DingJ, SchymickJC, WasheckaN, et al (2008) A genome-wide association study of sporadic ALS in a homogenous Irish population. Hum Mol Genet 17: 768–774.18057069 </plain></SENT>
</text></ref><ref id="pone.0072381-Landers1"><text><SENT sid="719" pm="."><plain>19 LandersJE, MelkiJ, MeiningerV, GlassJD, van den BergLH, et al (2009) Reduced expression of the Kinesin-Associated Protein 3 (KIFAP3) gene increases survival in sporadic amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A 106: 9004–9009.19451621 </plain></SENT>
</text></ref><ref id="pone.0072381-vanEs1"><text><SENT sid="720" pm="."><plain>20 van EsMA, Van VughtPW, BlauwHM, FrankeL, SarisCG, et al (2007) ITPR2 as a susceptibility gene in sporadic amyotrophic lateral sclerosis: a genome-wide association study. Lancet Neurol 6: 869–877.17827064 </plain></SENT>
</text></ref><ref id="pone.0072381-vanEs2"><text><SENT sid="721" pm="."><plain>21 van EsMA, VeldinkJH, SarisCG, BlauwHM, van VughtPW, et al (2009) Genome-wide association study identifies 19p13.3 (UNC13A) and 9p21.2 as susceptibility loci for sporadic amyotrophic lateral sclerosis. Nat Genet 41: 1083–1087.19734901 </plain></SENT>
</text></ref><ref id="pone.0072381-Coe1"><text><SENT sid="722" pm="."><plain>22 CoeBP, GirirajanS, EichlerEE (2012) The genetic variability and commonality of neurodevelopmental disease. Am J Med Genet C Semin Med Genet 160C: 118–129.22499536 </plain></SENT>
</text></ref><ref id="pone.0072381-Nassi1"><text><SENT sid="723" pm="."><plain>23 NassiP, NedianiC, LiguriG, TaddeiN, RamponiG (1991) Effects of acylphosphatase on the activity of erythrocyte membrane Ca2+ pump. J Biol Chem 266: 10867–10871.1645713 </plain></SENT>
</text></ref><ref id="pone.0072381-Chuang1"><text><SENT sid="724" pm="."><plain>24 ChuangL, WakuiK, SueWC, SuMH, ShafferLG, et al (2005) Interstitial deletion 11(p11.12p11.2) and analphoid marker formation results in inherited Potocki-Shaffer syndrome. Am J Med Genet A 133A: 180–183.15666301 </plain></SENT>
</text></ref><ref id="pone.0072381-Miller1"><text><SENT sid="725" pm="."><plain>25 MillerS, RogersHA, LyonP, RandV, Adamowicz-BriceM, et al (2011) Genome-wide molecular characterization of central nervous system primitive neuroectodermal tumor and pineoblastoma. Neuro Oncol 13: 866–879.21798848 </plain></SENT>
</text></ref><ref id="pone.0072381-Raish1"><text><SENT sid="726" pm="."><plain>26 RaishM, KhurshidM, AnsariMA, ChaturvediPK, BaeSM, et al (2012) Analysis of molecular cytogenetic alterations in uterine leiomyosarcoma by array-based comparative genomic hybridization. J Cancer Res Clin Oncol 138: 1173–1186.22419440 </plain></SENT>
</text></ref><ref id="pone.0072381-Ferlini1"><text><SENT sid="727" pm="."><plain>27 FerliniA, BovolentaM, NeriM, GualandiF, BalboniA, et al (2010) Custom CGH array profiling of copy number variations (CNVs) on chromosome 6p21.32 (HLA locus) in patients with venous malformations associated with multiple sclerosis. BMC Med Genet 11: 64.20426824 </plain></SENT>
</text></ref><ref id="pone.0072381-Katagiri1"><text><SENT sid="728" pm="."><plain>28 KatagiriT, Sato-OtsuboA, KashiwaseK, MorishimaS, SatoY, et al (2011) Frequent loss of HLA alleles associated with copy number-neutral 6pLOH in acquired aplastic anemia. Blood 118: 6601–6609.21963603 </plain></SENT>
</text></ref><ref id="pone.0072381-Lisle1"><text><SENT sid="729" pm="."><plain>29 LisleJE, Mertens-WalkerI, RutkowskiR, HeringtonAC, StephensonSA (2013) Eph receptors and their ligands: promising molecular biomarkers and therapeutic targets in prostate cancer. Biochim Biophys Acta 1835: 243–257.23396052 </plain></SENT>
</text></ref><ref id="pone.0072381-VanHoecke1"><text><SENT sid="730" pm="."><plain>30 Van HoeckeA, SchoonaertL, LemmensR, TimmersM, StaatsKA, et al (2012) EPHA4 is a disease modifier of amyotrophic lateral sclerosis in animal models and in humans. Nat Med 18: 1418–1422.22922411 </plain></SENT>
</text></ref></ref-list></SecTag></back></article>
